JP2024527535A5 - - Google Patents

Info

Publication number
JP2024527535A5
JP2024527535A5 JP2023579728A JP2023579728A JP2024527535A5 JP 2024527535 A5 JP2024527535 A5 JP 2024527535A5 JP 2023579728 A JP2023579728 A JP 2023579728A JP 2023579728 A JP2023579728 A JP 2023579728A JP 2024527535 A5 JP2024527535 A5 JP 2024527535A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
substituted
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023579728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527535A (ja
JP7843785B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2022/009980 external-priority patent/WO2023282702A1/ko
Publication of JP2024527535A publication Critical patent/JP2024527535A/ja
Publication of JP2024527535A5 publication Critical patent/JP2024527535A5/ja
Application granted granted Critical
Publication of JP7843785B2 publication Critical patent/JP7843785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023579728A 2021-07-09 2022-07-08 Shp2阻害剤及びその使用 Active JP7843785B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR10-2021-0090244 2021-07-09
KR10-2021-0090239 2021-07-09
KR20210090239 2021-07-09
KR20210090244 2021-07-09
KR10-2022-0031603 2022-03-14
KR20220031603 2022-03-14
PCT/KR2022/009980 WO2023282702A1 (ko) 2021-07-09 2022-07-08 Shp2 억제제 및 이의 용도

Publications (3)

Publication Number Publication Date
JP2024527535A JP2024527535A (ja) 2024-07-25
JP2024527535A5 true JP2024527535A5 (cg-RX-API-DMAC7.html) 2025-07-15
JP7843785B2 JP7843785B2 (ja) 2026-04-10

Family

ID=84801788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579728A Active JP7843785B2 (ja) 2021-07-09 2022-07-08 Shp2阻害剤及びその使用

Country Status (10)

Country Link
US (1) US12029739B2 (cg-RX-API-DMAC7.html)
EP (1) EP4368625A4 (cg-RX-API-DMAC7.html)
JP (1) JP7843785B2 (cg-RX-API-DMAC7.html)
KR (1) KR102682323B1 (cg-RX-API-DMAC7.html)
AU (1) AU2022309195B2 (cg-RX-API-DMAC7.html)
CA (1) CA3226206A1 (cg-RX-API-DMAC7.html)
IL (1) IL309984A (cg-RX-API-DMAC7.html)
MX (1) MX2024000271A (cg-RX-API-DMAC7.html)
TW (1) TW202319056A (cg-RX-API-DMAC7.html)
WO (1) WO2023282702A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023169170A1 (zh) * 2022-03-10 2023-09-14 捷思英达控股有限公司 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024125603A1 (zh) * 2022-12-15 2024-06-20 江苏威凯尔医药科技有限公司 Shp2抑制剂及其应用
AU2024206693A1 (en) * 2023-01-05 2025-06-26 Kanaph Therapeutics Inc. Shp2 inhibitor and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025110772A1 (ko) * 2023-11-22 2025-05-30 엘젠테라퓨틱스 주식회사 이미다졸로-피리딘 유도체 및 이의 용도
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520299A (ja) 2000-12-12 2004-07-08 ニューロジェン・コーポレーション スピロ[イソベンゾフラン−1,4’−ピペリジン]−3−オン類及び3h−スピロイソベンゾフラン−1,4’−ピペリジン類
EP1583747A2 (en) 2002-12-31 2005-10-12 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
CN117263942A (zh) 2018-03-21 2023-12-22 传达治疗有限公司 Shp2磷酸酶抑制剂及其使用方法
RU2020133727A (ru) * 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
EP3847744B1 (en) 2018-09-07 2025-01-15 Belimo Holding AG An actuator with an electric motor and a method of controlling the electric motor to maintain a current position
JP7337174B2 (ja) * 2018-09-18 2023-09-01 ニカング セラピューティクス, インコーポレイテッド Srcホモロジー-2ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
CN112839935A (zh) * 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
TW202028183A (zh) 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
MA53921A (fr) 2018-10-17 2022-01-26 Array Biopharma Inc Inhibiteurs de protéine tyrosine phosphatase
AU2020251841B2 (en) 2019-04-02 2025-01-30 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
WO2021043077A1 (zh) 2019-09-06 2021-03-11 四川科伦博泰生物医药股份有限公司 一种取代吡嗪化合物、其制备方法和用途
CN110734480B (zh) 2019-11-07 2021-08-24 中国科学院遗传与发育生物学研究所 大肠杆菌分子伴侣GroEL/ES在协助合成植物Rubisco中的应用
WO2021115286A1 (zh) 2019-12-10 2021-06-17 成都倍特药业股份有限公司 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物
WO2021147879A1 (zh) 2020-01-21 2021-07-29 贝达药业股份有限公司 Shp2抑制剂及其应用
TW202144334A (zh) 2020-04-03 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 含氮雜芳類衍生物游離鹼的晶型
CN115362149B (zh) 2020-04-26 2024-05-14 贝达药业股份有限公司 Shp2抑制剂及其组合物和应用
CN115279749B (zh) 2020-04-30 2024-05-10 贝达药业股份有限公司 Shp2抑制剂及其组合物和应用
TW202214584A (zh) 2020-07-24 2022-04-16 大陸商貝達藥業股份有限公司 Shp2抑制劑及其組合物和應用

Similar Documents

Publication Publication Date Title
KR102142177B1 (ko) Ezh2 억제용 하이드로클로라이드 염 형태
CN108290878B (zh) 新的膜铁转运蛋白抑制剂
KR20250120376A (ko) 축합환 화합물 및 이의 응용
JP4520533B2 (ja) 縮合アミノジヒドロチアジン誘導体
KR101635227B1 (ko) 벤젠 또는 티오펜 유도체 및 vap-1 억제제로서 이의 용도
KR20230070207A (ko) 항바이러스제로서 작용화된 펩티드
CN105085429B (zh) 芳杂环类衍生物及其在药物上的应用
JP7439018B2 (ja) 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
KR20220088375A (ko) 피롤아미드 화합물 및 그 용도
TW202034910A (zh) 非酒精性脂肪性肝病的治療
WO2024078592A1 (zh) 靶向成纤维细胞活化蛋白的药物及其应用
CN119708105A (zh) 甾体化合物及其应用
WO2023202642A1 (zh) Rho相关蛋白激酶抑制剂及其制备和应用
KR20240124324A (ko) 비스(아자니릴리덴)설포닐 구조를 함유하는 화합물 및 약제에서의 이의 용도
CN117580577A (zh) 肾损伤的预防和/或治疗用医药组合物以及自噬活化剂
CN119708106A (zh) 甾体化合物及其应用
CN119661618A (zh) 甾体化合物及其应用
KR20200112810A (ko) 헤테로아릴 아미드 화합물, 이에 대한 제조 방법, 이의 약학적 조성물 및 이의 적용
RU2024103122A (ru) Ингибитор shp2 и его применение
CN112979675A (zh) 一种小分子含硫杂环化合物
JP2024540402A (ja) 新規オーリスタチン類似体およびその免疫複合体
WO2023209368A1 (en) Nitrogen comprising heterocyclic derivatives for the treatment of disorders associated with gpr55 receptor
JP2025500404A (ja) 新規オーリスタチン類似体およびその免疫複合体
WO2015179697A1 (en) Compounds for the treatment of bacterial infections